Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher – Should You Buy?
Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX)
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX)
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
Turn Therapeutics' GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
Turn Therapeutics Appoints Arthur Golden to Board of Directors
U.S. IPO Weekly Recap: 6 IPOs Debut, Pipeline Grows, Despite Government Shutdown
Turn Therapeutics Announces Expected First Day of Trading on NASDAQ Global Market